Transdermal fentanyl (Duragesic): Respiratory arrest in adolescents;Fentanyl transdermique (Duragesic): Arrêt respiratoire chez des adolescents

CMAJ. Canadian Medical Association Journal

Volumn 171, Issue 8, 2004, Pages

  Raymond, Barbara ^a   Morawiecka, Iza ^a  

^a HEALTH CANADA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADHESIVE AGENT; FENTANYL; OPIATE; SHORT ACTING DRUG; SILICONE;

ADOLESCENT; BRAIN HYPOXIA; BRAIN INJURY; CANADA; CASE REPORT; CHRONIC PAIN; COGNITIVE DEFECT; DISEASE SEVERITY; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG DELIVERY SYSTEM; DRUG DOSE REGIMEN; DRUG FATALITY; DRUG INDICATION; DRUG LABELING; DRUG MARKETING; DRUG SAFETY; DRUG UPTAKE; FEMALE; HEADACHE; HUMAN; HYPOVENTILATION; INFECTIOUS MONONUCLEOSIS; MALE; NOTE; PATIENT EDUCATION; PHARMACOKINETICS; POSTOPERATIVE PAIN; PRESCRIPTION; RESPIRATION DEPRESSION; RESPIRATORY ARREST; RESUSCITATION; SORE THROAT;

EID: 19544365575     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: None     Document Type: Note

References (3)

1. Duragesic 25 (fentanyl transdermal system) [product monograph]. Toronto: Janssen-Ortho Inc.; 2002.
2. Grond S, Radbruch L, Lehmann KA. Clinical pharmacokinetics of transdermal opioids: focus on transdermal fentanyl. Clin Pharmacokinet 2000;38(1):59-89.
3. Kornick CA, Santiago-Palma J, Moryl N, Payne R, Obbens EA. Benefit-risk assessment of transdermal fentanyl for the treatment of chronic pain. Drug Saf 2003;26(13):951-73.